From:

To: ETF SMB Board Feedback; Sieg, Tricia - ETF
Subject: Question about GIB 5/17/2023 Item 3.C.
Date: Wednesday, May 17, 2023 10:23:46 AM

## CAUTION: This email originated from outside the organization.

Do not click links or open attachments unless you recognize the sender and know the content is safe.

## Hi GIB and Ms. Sieg:

I've been listening to the GIB meeting and am a state health plan member and volunteer as an advocate for those living with HIV. I have long advocated with health care providers, HIV/AIDS service organizations, and individuals living with HIV, that individuals apply for manufacturer copay assistance.

Thank you for your detailed explanation of the AGS program being proposed. (I googled to find Ms. Sieg's email address.). It sounds from what I know so far as a good program. It was interesting to hear of the opposition so far.

A question I have about the Copay Assistance Accumulator Program, now (in the meeting) called the Access Guidance Service Program. The discussion and printed materials largely talk about Level 4 specialty drugs, but mentions HIV drugs in passing.

(HIV drugs in the ETF Navitus formulary are currently Level 2, not Level 4, and have been for at least a couple of years, dating to when the two Specialty Pharmacies were required for all Level 4 drugs.)

Is the AGS program intended to cover all drugs with manufacturer copay assistance programs? What is the criteria for the drugs selected?



From: Sieg, Tricia - ETF To: Dan Ross

ETF SMB Board Feedback Cc:

Subject: RE: Question about GIB 5/17/2023 Item 3.C. Date: Wednesday, May 17, 2023 10:58:32 AM

Attachments:



Hi Dan,

Thank you for listening to the GIB Meeting today!

Navitus's Access Guidance Service (AGS) Program is intended to cover specialty drugs and HIV drugs. The only non-specialty drugs the AGS program covers are those HIV drugs that are on level 2. That is the criteria for the drugs that are included in the AGS program that the drugs be on the specialty drug tier (for our plan that's level 4) or HIV drugs on level 2.

If you have any questions or need anything please do not hesitate to let me know.

Have a great day!



## Tricia Sieg

Pharmacy Benefits Program Manager Strategic Health Policy Wisconsin Department of Employee Trust Funds | etf.wi.gov 608 261-6006 | 877 533-5020







🟏 🗭 🍯 in

Know your WRS Benefits and how they work! #WRSbenefits

Important Disclaimer: This email message and any attachments may contain information that is confidential, privileged, proprietary, or otherwise protected by law. This information is intended solely for the named addressee (or a person responsible for delivering it to the addressee). If you have received this message in error, please notify the sender immediately and delete it from your computer. Unauthorized disclosure, copying, printing, or distribution of this message is prohibited. **Sent:** Wednesday, May 17, 2023 10:23 AM

To: ETF SMB Board Feedback <ETFSMBBoardFeedback@etf.wi.gov>; Sieg, Tricia - ETF

<Tricia2.Sieg@etf.wi.gov>

**Subject:** Question about GIB 5/17/2023 Item 3.C.

CAUTION: This email originated from outside the organization.

Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi GIB and Ms. Sieg:

I've been listening to the GIB meeting and am a state health plan member and volunteer as an advocate for those living with HIV. I have long advocated with health care providers, HIV/AIDS service organizations, and individuals living with HIV, that individuals apply for manufacturer copay assistance.

Thank you for your detailed explanation of the AGS program being proposed. (I googled to find Ms. Sieg's email address.). It sounds from what I know so far as a good program. It was interesting to hear of the opposition so far.

A question I have about the Copay Assistance Accumulator Program, now (in the meeting) called the Access Guidance Service Program. The discussion and printed materials largely talk about Level 4 specialty drugs, but mentions HIV drugs in passing.

(HIV drugs in the ETF Navitus formulary are currently Level 2, not Level 4, and have been for at least a couple of years, dating to when the two Specialty Pharmacies were required for all Level 4 drugs.)

Is the AGS program intended to cover all drugs with manufacturer copay assistance programs? What is the criteria for the drugs selected?

